filmov
tv
Clinical trial combination therapy lowers risk of endometrial cancer progression
Показать описание
Stage IV endometrial cancer survivor Julie Dillard shares her experience with a clinical trial conducted by MD Anderson gynecologic oncologist Shannon Westin, M.D. The Phase III study found a PARP inhibitor plus immunotherapy lowered the risk of endometrial cancer progression over chemotherapy alone.
Clinical trial combination therapy lowers risk of endometrial cancer progression
IBD: Beyond Combination Therapy
A Unified Approach to Lower Risk MDS: Standard and Emerging Therapies
Locally advanced NSCLC: Combination therapy with targeted and immunotherapy agents
Medical Oncology Clinical Trials | eviCore Webinar Series
CLL: Sequencing Monotherapy vs. Combination Therapy
Updates in CLL - 2023 Best of Hematology Conference
Key highlights in CLL: clinical trial updates & the role of combination therapies and novel BTKi...
Continuous BTKi therapy in CLL: are time-limited combination therapies more beneficial?
Investigator Insights: Clinical Trial Endpoints and IBD Indices in Clinical Practice
IMbrave150 Trial: Combination Therapy in Advanced HCC
NRG-GU010 Clinical Trial: Can I Skip Hormone Therapy?
Ongoing clinical trials of ruxolitinib-based combinations in myelofibrosis
Novel treatment options for LR-MDS and the importance of clinical trials in this space
Non-Surgical Treatment Options & Clinical Trials
MPN Clinical Trial Updates for Physicians
Drug Delivering Therapies for Lower Extremity PAD
The Expanding Landscape of Therapeutic Targets in ALS Clinical Trials
Evidence of Efficacy for Add-On Therapy and Upfront Combination Therapy
Clinical Trials in Multiple Myeloma
Combined lower CETP and PCSK9 levels and risk of coronary artery disease | UMC Utrecht
Combination Therapy with JAK2 inhibitors in MPN
Stephen Lyle - Personalized medicine
What’s next for clinical trials in Alzheimer’s disease?
Комментарии